Are Investors Undervaluing Bausch + Lomb Corporation (NYSE:BLCO) By 33%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$22.22 Current share price of US$14.79 suggests Bausch + Lomb is potentially 33% undervalued The US
Simply Wall StApr 28 10:29 ET
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints Achieved Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live
BusinesswireApr 25 08:30 ET
Express News | RBC Capital Maintains Outperform on Bausch & Lomb, Lowers Price Target to $18
Moomoo 24/7Apr 22 11:39 ET
Bausch + Lomb Q1 Results Likely to Be Impacted by Foreign Exchange Headwinds, RBC Says
Bausch + Lomb's (BLCO) Q1 financial results are expected to be affected by continued foreign exchange headwinds, RBC Capital Markets said Monday. The eye health company is scheduled to report Q1 resul
MT NewswiresApr 22 10:50 ET
Express News | Bausch + Lomb Corp : RBC Cuts Target Price to $18 From $20: RBC Cuts Target Price to $18 From $20
Moomoo 24/7Apr 22 01:39 ET
Express News | Bausch + Lomb Announced Its ONE By ONE And Biotrue Eye Care Recycling Programs Have Collected 84.3M Units, Or 510,116 Pounds, Of Used Contact Lenses, Eye Care And Lens Care Materials In The U.S
Moomoo 24/7Apr 18 07:14 ET
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling programs have
BusinesswireApr 18 07:00 ET
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch +
BusinesswireApr 15 12:00 ET
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says
Bausch Health (BHC) received a "positive" appellate court ruling on Xifaxan, though the market is assigning only a 32% chance of Bausch + Lomb (BLCO) distribution, RBC Capital Markets said Friday in a
MT NewswiresApr 12 12:31 ET
Unusual Options Activity: SBUX, ROIV and Others Attract Market Bets, SBUX V/OI Ratio Reaches 111.0
EST Apr 5th Closing Delivery - In the last three hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
moomoo NewsApr 5 16:30 ET
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating
Bausch Health Companies (BHC) has an average rating of hold and price targets ranging from $7 to $16, according to analysts polled by Capital IQ. Price: 9.97, Change: -0.08, Percent Change: -0.8
MT NewswiresApr 5 08:42 ET
Express News | Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $17
Moomoo 24/7Apr 4 12:32 ET
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
Business WireMar 27 07:00 ET
Is Bausch + Lomb (NYSE:BLCO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Simply Wall StMar 24 10:00 ET
Benchmark Upgrades Emergent Biosolutions to Buy
Seeking AlphaMar 7 11:36 ET
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced
BusinesswireFeb 28 08:00 ET
Express News | Barclays Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $18
Moomoo 24/7Feb 26 06:54 ET
Bausch + Lomb Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceFeb 23 05:40 ET
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says
Bausch + Lomb (BLCO) faces market-related risks associated with its separation from Bausch Health (BHC), especially after the patent loss of Xifaxan, a treatment for travelers' diarrhea, RBC Capital M
MT NewswiresFeb 22 12:38 ET
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners
Dow JonesFeb 22 11:33 ET
No Data
No Data